Dataset Information

Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

ABSTRACT: To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia.Participants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study.In comparison to rimonabant (20mg/day), placebo-treated participants exhibited a significant improvement on the Repeatable Battery for the Assessment of Neuropsychological Status total score. In contrast, rimonabant was associated with significant improvement on a probabilistic learning task. There were no other significant treatment effects.Rimonabant did not improve global cognitive functioning, but did improve a specific learning deficit based on response to positive feedback.

SUBMITTER: Boggs DL

PROVIDER: S-EPMC3268840 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Boggs Douglas L DL Kelly Deanna L DL McMahon Robert P RP Gold James M JM Gorelick David A DA Linthicum Jared J Conley Robert R RR Liu Fang F Waltz James J Huestis Marilyn A MA Buchanan Robert W RW

Schizophrenia research 20111203 2-3

<h4>Objective</h4>To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia.<h4>Methods</h4>Participants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study.<h4>Results</h4>In comparison to rimonabant (20mg/day), placebo-treated participants exhibited a significant improvement on the Repeatable Battery for the Assessment of Neuropsychological Status total score. ...[more]

PMID: 22137462

Similar Datasets

Project description:BackgroundAlthough clozapine is an effective option for treatment-resistant schizophrenia (TRS), there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine. The main purpose of this randomized, double-blind, placebo-controlled trial was to explore the amisulpride augmentation efficacy on the psychopathological symptoms and cognitive function of clozapine-resistant treatment-refractory schizophrenia (CTRS) patients.MethodsA total of 80 patients were recruited and randomly assigned to receive initial clozapine plus amisulpride (amisulpride group) or clozapine plus placebo (placebo group). Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS), Clinical Global Impression (CGI) scale scores, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Treatment Emergent Symptom Scale (TESS), laboratory measurements, and electrocardiograms (ECG) were performed at baseline, at week 6, and week 12.ResultsCompared with the placebo group, amisulpride group had a lower PANSS total score, positive subscore, and general psychopathology subscore at week 6 and week 12 (PBonferroni < 0.01). Furthermore, compared with the placebo group, the amisulpride group showed an improved RBANS language score at week 12 (PBonferroni < 0.001). Amisulpride group had a higher treatment response rate (P = 0.04), lower scores of CGI severity and CGI efficacy at week 6 and week 12 than placebo group (PBonferroni < 0.05). There were no differences between the groups in body mass index (BMI), corrected QT (QTc) intervals, and laboratory measurements. This study demonstrates that amisulpride augmentation therapy can safely improve the psychiatric symptoms and cognitive performance of CTRS patients.ConclusionThis study indicates that amisulpride augmentation therapy has important clinical significance for treating CTRS to improve clinical symptoms and cognitive function with tolerability and safety. Trial registration Clinicaltrials.gov identifier- NCT03652974. Registered August 31, 2018, https://clinicaltrials.gov/ct2/show/NCT03652974.

Dataset Information

Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Publications

Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets